Clinical Trials Logo

Atherosclerosis clinical trials

View clinical trials related to Atherosclerosis.

Filter by:

NCT ID: NCT05974033 Not yet recruiting - Clinical trials for ICAS - Intracranial Atherosclerosis

IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)

Start date: August 2023
Phase: N/A
Study type: Interventional

A multicenter, open-label, blinded-endpoint, prospective, randomized controlled clinical trial with an "all comers" design.

NCT ID: NCT05969782 Active, not recruiting - Aortic Aneurysm Clinical Trials

The Enzen Trial: Comparison of Evar Endoprosthesis: Endurant Versus Zenith

ENZEN
Start date: July 1, 2023
Phase:
Study type: Observational

A prospective, non-randomized trial of patients submitted to EVAR for aortoiliac aneursym using Endurant II (Medtronic) or Zenith (Cook).

NCT ID: NCT05947994 Completed - Ischemic Stroke Clinical Trials

Credo Stent in the Symptomatic Intracranial Stenosis

CRESIS
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

In the symptomatic ischemic stroke, the decision-making of medical treatment plus intracranial stenting has been more and more popular, especially in patients with intracranial large severe stenosis or occlusive artery. Nonetheless, there were few evidences about times of intracranial stenting which compared beyond 7 days from acute ischemic stroke with the progressive ischemic stroke time. The purpose of this study was to compared the adverse events during 1-year follow-up of these two groups.

NCT ID: NCT05945030 Recruiting - Type2diabetes Clinical Trials

Correlation of Xanthelasma With Atherosclerosis, Hepatic Fat and Fibrosis

Start date: July 1, 2023
Phase:
Study type: Observational

Patients with diabetes with clinical feature of Xanthelasma will show increased Atherosclerosis. Objectives: Primary 1. To correlate xanthelasma and its severity to pulse wave velocity and atherosclerosis as see in carotid doppler. Secondary 2. To correlate xanthelasma to liver fat and fibrosis. Methodology: T2DM patient will be recruited from endocrine OPD 1. Clinical History and Examination: a. General Physical Examination: Height, weight, waist circumference, hip circumference, BMI, Blood Pressure, Hand grip. Xanthelasma. 2. Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits 1. Fasting blood Glucose 2. Haemoglobin A1C: The estimation of average blood sugar level over a period of two to three months will be analysed with the patient's blood sample for haemoglobin A1C based on turbidimetric inhibition immunoassay method (using COBAS 6000 analyser) 3. Lipid Profile: Fasting samples shall be analysed for lipid profile. Levels of total cholesterol (TC), serum triglyceride (TG) and high-density lipoprotein cholesterol (HDL-c) will be estimated using commercial kits (Randox Laboratory, USA). Value of low-density lipoprotein cholesterol (LDL-c) will be calculated according to Friedewald's equation. 4. Liver Function Tests: Fasting samples shall be analysed for liver function test. Levels of alkaline phosphate, Aspartate aminotransferase, Alanine aminotransferase and Gamma-glutamyl transferase will be estimated by using commercial kits (based on kinetic method). 3. Assessment of sub-clinical atherosclerosis: Pulse wave velocity and carotid Doppler will be done 1. Pulse wave velocity: Arterial stiffness indices will be analyzed by measuring carotid femoral pulse wave velocity. 2. Carotid Doppler: (based on kinetic method) 3. FibroScan Estimation: It is a medical diagnostic tool. Liver stiffness (LSM in kPa) and controlled attenuation parameter (CAP in dB/m) measurements will be done by transient elastography (FibroScan® 430 Touch, Echosens, FR) in order to quantify severity of liver fibrosis (LSM 7-10 kPa for F1, 10.1-13 for F2 and >13kPa for F≥3

NCT ID: NCT05932472 Recruiting - Clinical trials for Cardiovascular Diseases

Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial

ASPIRIN-C3
Start date: January 15, 2024
Phase: Phase 4
Study type: Interventional

Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.

NCT ID: NCT05908877 Not yet recruiting - Metabolic Syndrome Clinical Trials

Cardio-Metabolic Risk Evaluation in Overweight and Obese Children

CardMetSOb
Start date: July 10, 2023
Phase:
Study type: Observational

Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound parameters in order to stratify cardio-metabolic risk in obese children. Also, the specialized literature is poor regarding longitudinal follow-up and the importance of diet for reducing metabolic and cardiovascular complications in these children. This study is designed to assess the hypothesis that the sustained improvement of lifestyle with regard to nutrition and exercise can reverse cardiometabolic multimorbidities in obese children as assessed by clinical, biological and ultrasound evaluation.

NCT ID: NCT05908513 Withdrawn - Diabetes Mellitus Clinical Trials

NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM

RENEWAL
Start date: October 15, 2021
Phase: Phase 1
Study type: Interventional

Atherosclerosis and diabetes are related to coronary artery disease and peripheral artery disease. The mechanisms are related to increased reactive oxygen species (ROS) formation and inflammatory cytokine secretion. However, simply using antioxidant or anti-inflammatory therapies has no optimal outcomes. On the other hand, N-acetylcysteine (NAC) which has both antioxidant and anti-inflammatory effects could effectively attenuate ROS production and reduce vascular inflammation. Hence, we will investigate the effect of NAC treatment on the outcomes in patients with advanced atherosclerotic heart diseases and patients with diabetes combined with significant peripheral artery disease.

NCT ID: NCT05906810 Recruiting - Atherosclerosis Clinical Trials

Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Peri-implantitis and Peri-implant Mucositis

Start date: October 5, 2020
Phase: N/A
Study type: Interventional

A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with peri-implantitis/peri-implant mucositis and without any cardiovascular disease.

NCT ID: NCT05906797 Completed - Atherosclerosis Clinical Trials

Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.

Start date: September 7, 2020
Phase: N/A
Study type: Interventional

A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with periodontitis and without any cardiovascular disease.

NCT ID: NCT05901246 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Anti-eryptotic Effect of a Food Supplement With Plants Sterols in Hypercholesterolemia Treated With Statins

Start date: October 19, 2023
Phase: N/A
Study type: Interventional

Potential anti-eryptotic effect of a regular intake of a plant sterol (PS)-containing food supplement, in moderate hypercholesterolemic patients treated with the PS-containing food supplement or placebo supplement.